All News
ACR Best Abstracts - Day 2
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for #ACRbest abstracts today:
Is #Tofacitinib an option in #PMR poly myalgia rheumatica? RCT of Tofa 5 mg bid vs prednisone 15 mg/d and tapering. Equal results. Needs a phase 3 trial but could be an option if needing to avoid prednisone ex osteoporosis, DM, etc. abst#1107 #ACR22 @RheumNow https://t.co/OgcgslwaB5
Janet Pope Janetbirdope ( View Tweet)
Rhee @RennieRhee et al. Combined cranial vessel wall and orbital MRI for GCA. Improves sensitivity 77% vs 69% with loss of specificity 91% vs 95%. Identifies abnormalities in some without visual symptoms - at risk of vision loss @RheumNow #ACR22 Abstr#1618 https://t.co/OtGm7sEWtU https://t.co/YM4WLahubH
Richard Conway RichardPAConway ( View Tweet)
Sarilumab demonstrated efficacy in difficult to treat GC resistant PMR patients. Abs 1543 #ACR22 @RheumNow https://t.co/TCo5g5i1qh https://t.co/tZOhvvuhpY
Dr. Rachel Tate uptoTate ( View Tweet)
Refractory cystoid macular edema assoc'd w/ Bechet's uveitis can be effectively treated either with ADA, IFX or TCZ. Abs 1564 #ACR22 @RheumNow https://t.co/WcEI4d0Cl5 https://t.co/Tk0T41coog
Dr. Rachel Tate uptoTate ( View Tweet)
What imaging modality is best in GCA?
Dutch study: n=42
?GCA got all three of USS, PET/CT, MRI
Overall performance basically the same between all three.
Important details in 🧵
but reasonable to say you can be happy with whatever you’ve got!
ABST1617 #ACR22 #ACRBest @RheumNow https://t.co/HGt0vW9Z38
David Liew drdavidliew ( View Tweet)
Mazareeb et al. von Willebrand Factor in systemic vasculitis. Increased in active vasculitis compared to remission and HCs. Correlates disease activity. Not affected by IL6i. @RheumNow #ACR22 Abstr#1573 https://t.co/uJAFHQpOlu https://t.co/PNX0puOeCn
Richard Conway RichardPAConway ( View Tweet)
Sanchez Martin et al. Assessing effect tocilizumab by PET in GCA. Vascular involvement not generally fully controlled by tocilizumab. Not sure how PET was scored here. @RheumNow #ACR22 Abstr#1257 https://t.co/cGEoScnPb3 https://t.co/W0yYMPMjni
Richard Conway RichardPAConway ( View Tweet)
Exciting trial for PMR, SAPHYR RCT of sarilumab (IL6) in relapsing/refractory PMR
I interviewed Robert Speira aobut the trial for @RheumNow, arriving to your podcast inbox!
Overall very exciting, need options for this group and nice to see PMR getting attention
#ACR22 #ACRBest https://t.co/nPurVhpNws
Mike Putman EBRheum ( View Tweet)
Spiera et al. Resolution PMR in SAPHYR trial IL-6i sarilumab. Week 52, 81% vs 57% with no signs/symptoms More in PBO arm needed rescue GCs 58.6% vs 32.2% @RheumNow #ACR22 Abstr#1543 https://t.co/3Sr8aB2SpC https://t.co/mjuzNFWcdn
Richard Conway RichardPAConway ( View Tweet)
PJP occurs in pts w/ AAV who undergo treatment w/ CYC or RTX, but PJP PPX assoc'd w/ inc incidence of medication-related adverse events. Abs 1081 #ACR22 @RheumNow https://t.co/7vMgx7eMAP https://t.co/bhKPtJBMAO
Dr. Rachel Tate uptoTate ( View Tweet)
From my colleague @aili_yoyo. Mimics of vasculitis picked up on imaging. "Isolated abdominal vasculitis" is a surprisingly common consult. Can be tricky sometimes.
@RheumNow #ACR22 #mimics https://t.co/QfeaTHHzdA
Julian Segan JulianSegan ( View Tweet)
Rheumatic Masqueraders: Mimics of Rheumatic Diseases
Mimics of Vasculitis by
- Demographics
- Vascular Distribution
-**Imaging
- Labs
- Clinical Presentation
#ACR22 @RheumNow https://t.co/o0pZoiMqI2
Akhil Sood MD AkhilSoodMD ( View Tweet)
Mepolizumab assoc'd w/ clinical benefits in EGPA, including in patients w/ and w/o a vasculitic phenotype. Abs 1074 #ACR22 @RheumNow https://t.co/VCGhGaci8b https://t.co/OV8A1vsx1G
Dr. Rachel Tate uptoTate ( View Tweet)
Filho et al. Retrospective Brazilian study. ADA vs LEF in Takayasu arteritis. Comparable renission, relapses, steroid dose, ESR, CRP, imaging over median 15 weeks. More AEs in LEF but non-severe. @RheumNow #ACR22 Abstr#1553 https://t.co/499dUNmpUD https://t.co/AEk5cG7dc4
Richard Conway RichardPAConway ( View Tweet)
@EBRheum @RheumNow Its more than that…tubulointerstitial kidney disease, lymph nodes, salivary gland, and hepatobiliary tract disease don’t show findings of vasculitis.
Certain HLA haplotypes more linked with autoimmune diseases are present.
#ACR
@RheumNow
Fabio Torres FabioTorressav ( View Tweet)
Puechal et al RTX vs CYC induction in GPA: target trial emulation study. BVAS 0 and pred=<10mg at 6 months 73% RTX vs 40% CYC. RR 1.82[95%CI:1.22;2.73] @RheumNow #ACR22 Abstr#1084 https://t.co/6e8wutMC2H https://t.co/OpeajFVdJf
Richard Conway RichardPAConway ( View Tweet)
Terrier @TerrierBen et al Mepolizumab in vasculitic type EGPA in MIRRA. Vasculitic features similar in patients who did/did not achieve remission. Decreased flares of all type, including vasculitic. @RheumNow #ACR22 Abstr#1075 https://t.co/0MkJvnCnf1 https://t.co/ZxbDqlvgae
Richard Conway RichardPAConway ( View Tweet)
Roccatello et al. AAV with severe AKI. RTX+CYC+methylpred+no maintenance vs CYC+AZA maintenance. No difference in overall survival, 6-month therapeutic response rate, and 6-, and 12-month functional renal recovery. @RheumNow #ACR22 Abstr#1083 https://t.co/yv12bzwq6x https://t.co/YXUjpSzZ6I
Richard Conway RichardPAConway ( View Tweet)
GM-CSF/mavrilimumab in GCA masterclass from Maria Cid this morning.
Sadly, as John Stone & Sharon Chung ask and Maria Cid reflects on, we're not sure what happens next, despite the promising phase 2 & elegant MOA.
No current plans for a mavrilimumab GCA phase 3
#ACR22 @RheumNow https://t.co/c5PSqnFnC2
David Liew drdavidliew ( View Tweet)
